Apellis Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
May 31 2018 - 7:00AM
Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage
biopharmaceutical company focused on the development of novel
therapeutic compounds to treat disease through the inhibition of
the complement system, today announced that it will present at the
Jefferies 2018 Global Healthcare Conference on Friday, June 8, 2018
at 9:00 a.m. Eastern Time at the Grand Hyatt in New York City.
The presentation will be given by Apellis founder and chief
executive officer Cedric Francois, MD, PhD, and will be available
via live webcast from the “Events and Presentations” page of the
“Investors and Media” section of the Company’s website at
http://www.apellis.com. Replay of the webcast will be available for
90 days following the event.
About ApellisApellis Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company focused on the development
of novel therapeutic compounds for the treatment of a broad range
of life-threatening or debilitating autoimmune diseases based upon
complement immunotherapy through the inhibition of the complement
system at the level of C3. Apellis is the first company to advance
chronic therapy with a C3 inhibitor into clinical trials. For
additional information about Apellis and APL-2, please visit
http://www.apellis.com.
Forward-Looking Statements Statements in this
press release about future expectations, plans and prospects,
as well as any other statements regarding matters that are not
historical facts, may constitute “forward-looking statements”
within the meaning of The Private Securities Litigation Reform Act
of 1995. These statements include, but are not limited to,
statements relating to the implications of preliminary clinical
data. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “will,” “would” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including: whether preliminary or
interim results from a clinical trial will be predictive of the
final results of the trial; whether results obtained in preclinical
studies and clinical trials such as the results referenced in this
release will be indicative of results that will be generated in
future clinical trials; whether APL-2 will successfully advance
through the clinical trial process on a timely basis, or at all;
whether the results of such clinical trials will warrant regulatory
submission; whether APL-2 will receive approval from
the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether, if Apellis’
products receive approval, they will be successfully distributed
and marketed; whether Apellis’ cash resources will be sufficient to
fund the company's foreseeable and unforeseeable operating expenses
and capital expenditure requirements; and other factors discussed
in the “Risk Factors” section of Apellis’ Quarterly Report on Form
10-Q filed with the Securities and Exchange
Commission on April 30, 2018, and the risks described in
other filings that Apellis may make with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof,
and Apellis specifically disclaims any obligation to
update any forward-looking statement, whether as a result of new
information, future events or otherwise.
Investor Contact: Alex Kane
akane@w2ogroup.com 212.301.7218 (office)
929.400.2691 (mobile)
Media Contact:Tully Nicholas
tnicholas@denterlein.com617.482.0042 (office) 860.490.0218
(mobile)
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Apr 2024 to May 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From May 2023 to May 2024